BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
6/46
0.7 / 5 stars
All 46 Win/Lose results and 74 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 9 losses, 2 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBDTX / S&P -13.15% / 15.20% |
LoseBDTX / S&P -100.00% / 15.00% |
LoseBDTX / S&P -421.74% / 50.40% |
| 2026-Q10/3 |
LoseBDTX / S&P -12.35% / -4.33% |
LoseBDTX / S&P -100.00% / 11.30% |
LoseBDTX / S&P -1366.67% / 27.70% |
| 2025-Q40/2 |
LoseBDTX / S&P -35.88% / 2.65% |
No dataBDTX / S&P / 9.00% |
LoseBDTX / S&P -129.92% / 13.40% |
| 2025-Q31/2 |
WinBDTX / S&P 52.82% / 8.12% |
No dataBDTX / S&P / 4.61% |
LoseBDTX / S&P -127.07% / 13.45% |
| 2025-Q21/2 |
WinBDTX / S&P 60.00% / 10.94% |
No dataBDTX / S&P / 4.83% |
LoseBDTX / S&P -115.33% / 10.63% |
| 2025-Q10/2 |
LoseBDTX / S&P -27.57% / -4.27% |
No dataBDTX / S&P / 4.98% |
LoseBDTX / S&P -103.61% / 10.57% |
| 2024-Q40/2 |
LoseBDTX / S&P -50.80% / 2.41% |
No dataBDTX / S&P / 5.25% |
LoseBDTX / S&P -32.45% / 6.15% |
| 2024-Q30/2 |
LoseBDTX / S&P -6.65% / 5.89% |
No dataBDTX / S&P / 5.89% |
LoseBDTX / S&P -37.56% / 6.11% |
| 2024-Q20/2 |
LoseBDTX / S&P -8.09% / 4.28% |
No dataBDTX / S&P / 5.38% |
LoseBDTX / S&P -34.21% / 5.12% |
| 2024-Q11/2 |
WinBDTX / S&P 80.43% / 10.56% |
No dataBDTX / S&P / 5.71% |
LoseBDTX / S&P -30.54% / 5.59% |
| 2023-Q40/2 |
LoseBDTX / S&P -2.09% / 11.69% |
No dataBDTX / S&P / 6.81% |
LoseBDTX / S&P -25.40% / 7.78% |
| 2023-Q30/2 |
LoseBDTX / S&P -43.17% / -3.27% |
No dataBDTX / S&P / 7.52% |
LoseBDTX / S&P -19.32% / -5.03% |
| 2023-Q21/2 |
WinBDTX / S&P 167.20% / 8.74% |
No dataBDTX / S&P / 9.50% |
LoseBDTX / S&P -24.25% / -8.57% |
| 2023-Q10/2 |
LoseBDTX / S&P 5.00% / 7.50% |
No dataBDTX / S&P / 10.77% |
LoseBDTX / S&P -28.23% / -15.69% |
| 2022-Q40/2 |
LoseBDTX / S&P 6.51% / 7.56% |
No dataBDTX / S&P / 11.88% |
LoseBDTX / S&P -27.38% / -17.99% |
| 2022-Q30/2 |
LoseBDTX / S&P -31.30% / -4.88% |
No dataBDTX / S&P / 13.47% |
LoseBDTX / S&P -22.12% / -1.41% |
| 2022-Q21/2 |
WinBDTX / S&P -11.19% / -16.10% |
No dataBDTX / S&P / 13.71% |
LoseBDTX / S&P 3.08% / 11.04% |
| 2022-Q10/2 |
LoseBDTX / S&P -48.03% / -4.60% |
No dataBDTX / S&P / 15.97% |
LoseBDTX / S&P 39.92% / 42.23% |
| 2021-Q40/2 |
LoseBDTX / S&P -37.00% / 11.03% |
No dataBDTX / S&P / 15.00% |
LoseBDTX / S&P 69.27% / 96.40% |
| 2021-Q30/1 |
LoseBDTX / S&P -30.60% / 0.58% |
No dataBDTX / S&P / 10.77% |
No dataBDTX / S&P / 69.42% |
| 2021-Q20/1 |
LoseBDTX / S&P -49.75% / 8.55% |
No dataBDTX / S&P / 6.58% |
No dataBDTX / S&P / 51.81% |
| 2021-Q10/1 |
LoseBDTX / S&P -24.31% / 6.17% |
No dataBDTX / S&P / -1.06% |
No dataBDTX / S&P / 7.39% |
| 2020-Q40/1 |
LoseBDTX / S&P 6.02% / 12.15% |
No dataBDTX / S&P / -3.72% |
No dataBDTX / S&P / -33.42% |
| 2020-Q30/1 |
LoseBDTX / S&P -28.30% / 8.93% |
No dataBDTX / S&P / -2.04% |
No dataBDTX / S&P / -27.10% |
| 2020-Q21/1 |
WinBDTX / S&P 68.98% / 20.54% |
No dataBDTX / S&P / -0.46% |
No dataBDTX / S&P / -27.11% |
| 2020-Q10/0 |
No dataBDTX / S&P / -19.60% |
No dataBDTX / S&P / 3.47% |
No dataBDTX / S&P / -14.75% |
| 2019-Q40/0 |
No dataBDTX / S&P / 9.07% |
No dataBDTX / S&P / 5.36% |
No dataBDTX / S&P / 2.99% |
| 2019-Q30/0 |
No dataBDTX / S&P / 1.70% |
No dataBDTX / S&P / 5.02% |
No dataBDTX / S&P / 0.21% |
| 2019-Q20/0 |
No dataBDTX / S&P / 4.30% |
No dataBDTX / S&P / 6.64% |
No dataBDTX / S&P / 8.65% |
| 2019-Q10/0 |
No dataBDTX / S&P / 13.65% |
No dataBDTX / S&P / 8.12% |
No dataBDTX / S&P / 14.29% |
| 2018-Q40/0 |
No dataBDTX / S&P / -13.52% |
No dataBDTX / S&P / 9.05% |
No dataBDTX / S&P / 18.23% |
| 2018-Q30/0 |
No dataBDTX / S&P / 7.71% |
No dataBDTX / S&P / 10.21% |
No dataBDTX / S&P / 19.06% |
| 2018-Q20/0 |
No dataBDTX / S&P / 3.43% |
No dataBDTX / S&P / 9.03% |
No dataBDTX / S&P / 14.46% |
| 2018-Q10/0 |
No dataBDTX / S&P / -0.76% |
No dataBDTX / S&P / 7.68% |
No dataBDTX / S&P / 12.46% |
| 2017-Q40/0 |
No dataBDTX / S&P / 6.64% |
No dataBDTX / S&P / 7.03% |
No dataBDTX / S&P / 13.82% |
| 2017-Q30/0 |
No dataBDTX / S&P / 4.48% |
No dataBDTX / S&P / 5.68% |
No dataBDTX / S&P / 17.57% |
| 2017-Q20/0 |
No dataBDTX / S&P / 3.09% |
No dataBDTX / S&P / 4.83% |
No dataBDTX / S&P / 17.74% |
| 2017-Q10/0 |
No dataBDTX / S&P / 6.07% |
No dataBDTX / S&P / 3.67% |
No dataBDTX / S&P / 13.32% |
| 2016-Q40/0 |
No dataBDTX / S&P / 3.82% |
No dataBDTX / S&P / 2.09% |
No dataBDTX / S&P / 7.05% |
| 2016-Q30/0 |
No dataBDTX / S&P / 3.85% |
No dataBDTX / S&P / 0.20% |
No dataBDTX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BDTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -17.45% | 20.78% |
| Annualized return | -17.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | BDTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -78.13% | 83.14% |
| Annualized return | -26.22% | 12.86% |
10Y · 2020-01-31 to 2026-08-27
| Metric | BDTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.95% | 319.30% |
| Annualized return | -24.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |